These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30177584)

  • 41. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
    Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
    Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparing trastuzumab-related cardiotoxicity between elderly and younger patients with breast cancer: a prospective cohort study.
    Aladwani A; Mullen A; Alrashidi M; Alfarisi O; Alterkait F; Aladwani A; Kumar A; Boyd M; Eldosouky ME
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7643-7653. PubMed ID: 34982426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab.
    Liu X; Tao L; Wang M; Li H; Xu W
    Clin Breast Cancer; 2023 Jan; 23(1):23-31. PubMed ID: 36384817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.
    Bian SX; Korah MP; Whitaker TR; Ji L; Groshen S; Chung E
    Clin Breast Cancer; 2017 Nov; 17(7):510-515. PubMed ID: 28412326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
    El-Sherbeny WS; Sabry NM; Sharbay RM
    J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.
    Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Chow CM; Thavendiranathan D; Haq R; Barfett JJ; Petrella TM; Connelly KA; Yan AT
    Int J Cardiol; 2018 Jun; 261():228-233. PubMed ID: 29555336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
    Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer.
    Lorenzini C; Lamberti C; Aquilina M; Rocca A; Cortesi P; Corsi C
    J Am Soc Echocardiogr; 2017 Nov; 30(11):1103-1110. PubMed ID: 28822666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
    Bouwer NI; Steenbruggen TG; Rier HN; Kitzen JJEM; Smorenburg CH; van Bekkum ML; de Jong PC; Drooger JC; Holterhues C; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Int J Cancer; 2022 Aug; 151(4):616-622. PubMed ID: 35403708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.
    Bouwer NI; Jager A; Liesting C; Kofflard MJM; Brugts JJ; Kitzen JJEM; Boersma E; Levin MD
    Breast; 2020 Aug; 52():33-44. PubMed ID: 32361151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac monitoring during trastuzumab therapy in metastatic breast cancer: early incidence of cardiac dysfunction.
    Perone F; Zamora Auñon P; Rodríguez L; Vinal D; Caro-Codon J; Pertejo A; Martínez Marín V; Espinosa E; López-Fernández T
    Monaldi Arch Chest Dis; 2022 Feb; 92(4):. PubMed ID: 35179011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
    Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
    Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy.
    Huang P; Dai S; Ye Z; Liu Y; Chen Z; Zheng Y; Shao X; Lei L; Wang X
    Oncotarget; 2017 Jan; 8(2):2069-2075. PubMed ID: 27906683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
    de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.